Key facts
- This page summarizes Karen S. Lynch's Form 4 filing for CVS HEALTH Corp (CVS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Apr 2024, 16:47.
Karen S. Lynch - 01 Apr 2024 Form 4 Insider Report for CVS HEALTH Corp (CVS)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- CVS
- Reported as of
- 01 Apr 2024
- Net transaction value
- +$13,635,152
- SEC form
- 4
- Accepted by SEC
- 03 Apr 2024, 16:47:56 UTC
- Prior SEC filing
- 14 Feb 2024
- Next SEC filing
- 21 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karen S. Lynch
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Karen S. Lynch filed Form 4 for CVS HEALTH Corp (CVS) on 03 Apr 2024.
Change
- Previous filing in this sequence was filed on 14 Feb 2024.
- Current net transaction value: +$13,635,152.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CVS
transaction
Common Stock (Restricted)
Award
- Transaction value
- $3,599,931
- Shares
- +45,248
- Change %
- Price
- $79.56
- Shares after
- 45,248
- Date
- 01 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
CVS
transaction
Common Stock
Tax liability
- Transaction value
- $4,928,981
- Shares
- -61,953
- Change %
- -45%
- Price
- $79.56
- Shares after
- 74,687
- Date
- 01 Apr 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CVS
transaction
Derivative
Stock Option
Award
- Transaction value
- $14,964,202
- Shares
- +188,087
- Change %
- Price
- $79.56
- Shares after
- 188,087
- Date
- 01 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 188,087
- Exercise price
- $79.56
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in four equal annual installments, commencing 4/1/2025.
Footnote F2
Surrender of shares in payment of withholding taxes due upon the vesting and settlement of performance stock units.
Footnote F3
Option becomes exercisable in four equal annual installments, commencing 4/1/2025.